IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?

Abstract

The manuscript examines the role of isocitrate dehydrogenase 1 and the IDH1 gene in the prognosis and therapy of glial tumors.

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

“…MT cancers (1,(13)(14)(15). This hypothesis is supported by in vitro studies, showing that overexpression of IDH1 R132H sensitizes glioma cells to ionizing radiation (IR) or chemotherapy with carmustine (BCNU), cis-diaminedichloroplatinum (CDDP), or temozolomide (15)(16)(17).…”

Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide

“…Recently, a mutation affecting codon 132 of the isocitrate dehydrogenase 1 gene (IDH1), located on chromosome 2q33, was shown to be present in World Health Organization (WHO) Grade II-III gliomas and glioblastomas arising from lower grade gliomas [1][2][3][4][5][6][7][8][9][10][11][12]. Here, we retrospectively investigated the prognostic factors including histological subtype, 1p19q codeletion, MGMT promoter methylation status, and IDH1 mutation in recurrent anaplastic glioma patients who were treated with prolonged administration of TMZ.…”

Expression of cytosolic NADP+-dependent isocitrate dehydrogenase in melanocytes and its role as an antioxidant

“…IDPc mutation was inversely associated with grade in diffuse glial tumors and indeed, IDPc mutation can be a very strong prognostic factor in diffuse glioma [50]. In melanoma, IDPc mutation works with other oncogenic mutations and could contribute to the metastasis of melanoma [49].…”

“…In melanoma, IDPc mutation works with other oncogenic mutations and could contribute to the metastasis of melanoma [49]. Hypotheses regarding the role of IDPc mutation on tumor development were developed as follows [50]: (1) mutant IDPc cells may be more sensitive to genetic instability in response to oxidative stress, due to the loss of the antioxidant function of IDPc; (2) mutant IDPc cells may be less protective against anticancer therapy as a source of ROS.…”